Calgary, Alberta–(Newsfile Corp. – February 18, 2026) – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel“), announces the award of 50,001 deferred share units (“DSUs“) to Marvel’s three independent directors, in lieu of cash payment for directors’ fees. The DSUs …
Read More »
Matribhumi Samachar English